SOURCE: Cannabis Science, Inc.

Cannabis Science, Inc.

November 24, 2015 11:21 ET

Analyst Initiates Coverage on Cannabis Science w/ Accumulate Recommendation and $0.10 PPS Target as Company Advances Additional Product Lines in California and Gears Up for Animal Healthcare Entry Through Equi-Pharm

COLORADO SPRINGS, CO--(Marketwired - Nov 24, 2015) -  Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabis-based medicines, received a copy of an independent analyst report based on its new products approaching launch in California as well as their initial entry into the pet health industry.

The analyst authoring the report initiated coverage with an 'Accumulate' recommendation and a near-term target price per share of $0.05 with a long term target price per share of $0.10.

These analyses were supported by research showing that Americans spent an all-time high of $55.7 billion on their pets last year with expected spending to approach $60 billion this year. Cannabis Science is very excited to enter into the multi-billion dollar Animal Healthcare industry very soon through their subsidiary, Equi-Pharm.

You can read this report in its entirety at

About Cannabis Science, Inc.

Cannabis Science, Inc. takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.

Forward-Looking Statements

This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements. Safe Harbor Statement. The Private Securities Litigation Reform Act of 1995 provides a 'safe harbor' for forward-looking statements. Certain of the statements contained herein, which are not historical facts are forward looking statements with respect to events, the occurrence of which involved risks and uncertainties. These forward-looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the company are detailed from time to time in the company's reports filed with the Securities and Exchange Commission.

Contact Information